Skip to content

Medical Dermatology

Facing the world is not always easy for patients suffering from serious skin disorders. Dedicated to meeting the needs of these patients and their physicians, Allergan has developed some of the most technologically advanced dermatology products to treat skin disease as well as enhance the appearance of healthy skin.

According to the National Institutes of Health, between 5.8 and 7.5 million Americans suffer from psoriasis1, which is a chronic skin disorder than can take many different forms. An estimated 80 percent of all people between the ages of 11 and 30 have acne outbreaks at some point.2 Our dermatology portfolio includes TAZORAC® (tazarotene), the first topical receptor selective retinoid approved for psoriasis.

Another common chronic condition affecting an estimated 7.8 million Americans is hyperhidrosis, which is the term for excessive sweating.3 Patients with hyperhidrosis produce an amount of sweat that far exceeds that needed to regulate body temperature. Our medical dermatology portfolio includes BOTOX® (onabotulinumtoxinA) for severe primary axillary hyperhidrosis (excessive underarm sweating) that is not adequately managed by topical agents.

Important Information about TAZORAC® 
Important Information about BOTOX® 


  1. National Psoriasis Foundation Web site. "About Psoriasis: Statistics." Available at http://www.psoriasis.org/about/stats/index.php. Accessed November 13, 2007
  2. National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health. What is acne? Fast facts: an easy-to-read series of publications for the public. Available at: http://www.niams.nih.gov/health_info/acne/default.asp#acne_d. Accessed May 29, 2007
  3. American Academy of Dermatology. Press Release: Effective treatments mean excessive sweating patients no longer swimming in anxiety. February 9, 2004